Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial

Livingstone, E.; Gogas, H.; Kandolf-Sekulovic, L.; Meier, F.; Eigentler, T. K.; Ziemer, M.; Terheyden, P. A. M.; Gesierich, A. H.; Herbst, R. A.; Kaehler, K. C.; Ziogas, D. C.; Mijuskovic, Z.; Garzarolli, M.; Garbe, C.; Roesch, A.; Ugurel, S.; Gutzmer, R.; Grob, J. J.; Kiecker, F.; Utikal, J.; Windemuth-Kieselbach, C.; Eckhardt, S.; Zimmer, L.; Schadendorf, D.

Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial

Author:

Livingstone, E.; Gogas, H.; Kandolf-Sekulovic, L.; Meier, F.; Eigentler, T. K.; Ziemer, M.; Terheyden, P. A. M.; Gesierich, A. H.; Herbst, R. A.; Kaehler, K. C.; Ziogas, D. C.; Mijuskovic, Z.; Garzarolli, M.; Garbe, C.; Roesch, A.; Ugurel, S.; Gutzmer, R.; Grob, J. J.; Kiecker, F.; Utikal, J.; Windemuth-Kieselbach, C.; Eckhardt, S.; Zimmer, L.; Schadendorf, D.

Tübinger Autor(en):

Eigentler, Thomas
Garbe, Claus

Published in:

European Journal of Cancer (2023), Bd. 190, Article 112941

Verlagsangabe:

Oxford : Elsevier Sci Ltd

Language:

English

Full text:

http://dx.doi.org/10.1016/j.ejca.2023.112941

ISSN:

0959-8049